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with reference to programs a hundred years ago, when
contemporary pesticides and biological and cultural controls
did not exist and the tools of mosquito control were limited
to such measures as deep-ditch draining of wetlands in New
Jersey, clear-cutting, and use of arsenic compounds and
crude petroleum for larval control. Deep-ditch draining was
also practiced long ago in other states, such as Florida.
It was but half a century ago, after World War II, that
chlorinated hydrocarbons such as DDT came into wide-
spread use for mosquito control until they were banned, and
organophosphates such as malathion and naled took their
place. For cost and performance reasons, DDT continues to
be used in several developing countries for mosquito control.
Mr. Rupp refers to old reports of water management as a
means of making land formerly considered useless into
productive land capable of generating tax revenues. Today,
this practice would be considered wetlands conversion and
wildlife habitat destruction.
Robert Ward’s article in the latest Florida Mosquito
Control Association’s Wing Beats reminisces about the
venerable thermal fog machine, “those hot smelly ‘smokers’
belching up to eighty gallons of fog material per
hour...fireballs, greasy streets and cars, or blinded drivers”
(2). Back in those days, many children chased them on
bicycles, ignorant of pesticide risks that are now known.
Even in recent history, broad-spectrum organophosphates
such as parathion and chlorpyrifos, which have potent
nontarget effects, were used in aquatic habitats to control
mosquito larvae.
Mr. Rupp’s comments focus mainly on the mosquito
control of a century ago, when the stakes were high because
of malaria and yellow fever. The pioneers in mosquito
control did marvelous work with the limited tools available
to them and their limited knowledge of environmental
consequences, but the history of mosquito control has had
its time of pesticide reliance and has truly evolved to
today’s fully integrated mosquito management as briefly
described in the article.
Robert I. Rose
U.S. Department of Agriculture, Riverdale, Maryland, USA
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Enteric Fever Treatment Failures: A Global Concern
To the Editor: We read with great interest the report by
Threlfall et al. (1) of decreased susceptibility to ciprofloxa-
cin in Salmonella enterica serotype Typhi from the United
Kingdom. The authors indicate that nalidixic acid-resistant
S. Typhi with decreased susceptibility to ciprofloxacin is
now endemic in India and neighboring countries, constitut-
ing a threat to global health. The data are consistent with
previous studies from India (2-4). Despite the wide applica-
tions and broad-spectrum efficacy of fluoroquinolones,
resistance is increasingly observed in many species of gram-
negative organisms, including Salmonella. Detection in any
part of the world of even a few resistant strains with higher
MICs to ciprofloxacin is of concern to clinicians and
microbiologists. We report our recent observations in cases
of treatment failure of enteric fever caused by S. enterica
serotypes Typhi and Paratyphi A.
Fluoroquinolones have been in use for >15 years and
have remained an extremely important weapon against
infections. Ciprofloxacin is used widely in India to treat
many human infections, even without prescription, al-
though recommendations limit its use to enteric cases
caused by multidrug-resistant (MDR) strains. However,
concern is increasing that widespread use of these and
newer drugs will result in development of resistance
against them. Recently, reports have increased worldwide
concerning reduced activity of ciprofloxacin and allied drugs
against many infectious agents, including Salmonella (2-4).
In an ongoing study of drug susceptibility following
E-test, >12% of recent isolates of S. typhi in our institution
have shown increased MICs to ciprofloxacin (range 1.0 to
2.0 µg/mL), with 3% as high as 2.5 µg/mL (3-4). Of >100
strains screened recently, 4 of 18 MDR strains had in-
creased resistance to ciprofloxacin. Of the rest, 9 of 82 had
higher MICs to ciprofloxacin alone but were not MDR, and 2
were cases of double infection with S. Typhi and S.
Paratyphi A, common serotypes causing enteric fever in our
region. Because resistance to the quinolone group of drugs
(caused by gene mutations) develops independent of that in
other drugs, which are plasmid encoded, it also may develop
in otherwise sensitive strains.
However, our recent observations differ from those of
Dr. Threlfall, as well as from past data from India. We have
observed that treatment failures did not always correlate
with higher MICs to nalidixic acid and ciprofloxacin alone.
We have also noted a declining rate of MDR in S. Typhi,
reflecting increased sensitivity to chloramphenicol, amox-
icillin, and trimethoprim. However, S. Paratyphi A showed
relatively increased resistance to these drugs. The increas-
ing resistance to ciprofloxacin, to which enteric fever
treatment failures are often attributed, is now mainly
caused by strains susceptible to other common drugs.
Drs. Threlfall and Ward stated that >50% of strains
with decreased susceptibility to ciprofloxacin were MDR (1).
In contrast, our findings suggest that, despite prolonged
doses of ciprofloxacin, treatment failures are still common
with isolates sensitive to ciprofloxacin and nalidixic acid.
Drs. Threlfall and Ward also emphasized that MDR cases
with reduced sensitivity to ciprofloxacin are mainly trans-
mitted by travelers returning from India and Pakistan. This
conclusion would be justified as long as phage type E1,
comprising MDR strains with higher MICs to ciprofloxacin,
is endemic in India. However, problems of reduced action by
ciprofloxacin are now thought to be independent of MDR, to
result from many other factors, and thus to be of global
origin and incidence. Overall, we observe a much higher
rate than in the past of reduced susceptibility in S. Typhi
and S. Paratyphi A in our region, causing delayed response
in enteric patients. The increasing enteric fever treatment
failures noted by our clinicians indicate the need for careful
screening of recent isolates.
Fluoroquinolone resistance usually results from
mutations in genes for drug targets (gyrA and parC) or
potential of the drug being marked as a substrate as a
result of overexpression of drug-efflux pumps (5). Drug
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resistance attributable to efflux has been reported in a
number of gram-negative species, including Salmonella and
Pseudomonas. Strains expressing efflux mechanisms
leading to fluoroquinolone resistance are cross-resistant to
a number of structurally unrelated antimicrobial agents,
permitting multidrug resistance to develop (6). Therefore,
inhibition of efflux systems as targets of therapeutic
intervention would help prevent emergence of resistance to
fluoroquinolones and associated drugs and would further
potentiate drug activity. Bacteria exposed to concentrations
near their MIC values readily undergo selection for resis-
tance to ciprofloxacin (7). Hence, dosing regimens account-
ing for both treatment efficacy and susceptibility of clinical
pathogens should help control drug resistance that causes
frequent treatment failures (8).
Emerging resistance to antimicrobial agents by inter-
acting pathogens is not solely responsible for treatment
failures, since many other factors may be involved, e.g.,
inappropriate antibiotic regimen and dose selection, poor
patient compliance, and drug-drug and drug-host interac-
tions. One clinically important drug interaction involving
fluoroquinolones is not only by coadministration with other
drugs but also results from chelation to divalent and
trivalent cations, such as in antacids, iron compounds, or
dairy products; such chelation prevents most of the drugs
from being absorbed (9).
Efforts should be aimed at shortening treatment
duration by adopting efficacious drugs, since rapid, com-
plete eradication of an infecting organism may limit the
development of drug resistance. In addition, the rapid and
sensitive detection by molecular methods of invasive
disease due to Salmonella may help avoid overtreatment for
fever of unknown origin (10). Finally, development of newer
drugs offering similar activity against both enzyme targets
(DNA gyrase and topoisomerase-IV), as well as an
improved therapeutic index, will definitely strengthen
clinical practice.
The challenge ahead is to further our understanding of
newer antimicrobial resistance mechanism possibilities
stemming from the recent development of structurally
modified fluoroquinolones. Additional studies should assess
the relevance of pharmacodynamic modeling in determining
dosing or predicting efficacy and clinical management for
various indications in different patient populations.
Dinesh S. Chandel and Rama Chaudhry
All India Institute of Medical Sciences, New Delhi, India
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Enteric Fever Treatment Failures—Reply to Drs.
Chandel and Chaudhry
To the Editor: We are pleased that Drs. Chandel and
Chaudhry support our concern that the development of low-
level resistance to fluoroquinolone antimicrobial agents in
Salmonella enterica serotype Typhi is a threat to health in
both developing and developed countries. They cite their
article (1) reporting the recent emergence in India of strains
of S. Paratyphi A resistant to nalidixic acid and with low-
level resistance to ciprofloxacin. This finding has also been
observed in the United Kingdom, with >30% of S. Paratyphi
A infections in 2000 being caused by strains with decreased
susceptibility to ciprofloxacin. Of these strains, only one
was also resistant to other antimicrobial agents.
Our findings and those of Chandel and Chaudhry
clearly demonstrate the inadvisability of the use of ciprof-
loxacin in the Indian Subcontinent to treat many human
infections, regardless of prescription. To maintain the
efficacy of fluoroquinolones in both developing and devel-
oped countries, this class of antimicrobial agents must be
reserved for treatment of invasive disease and not for
prophylaxis. For travelers visiting developing countries,
ciprofloxacin must be used only when absolutely necessary
and not for treatment of uncomplicated gastroenteritis or
for travelers’ diarrhea syndromes.
E. John Threlfall and Linda R. Ward
Central Public Health Laboratory, London, United Kingdom
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Mycobacterium tuberculosis Beijing
Genotype, Thailand—Reply to Dr. Prodinger
To the Editor: We read with interest the report on the
occurrence of Mycobacterium tuberculosis strains of the
Beijing genotype in Thailand (1). In contrast to our findings
in Vietnam (2), Prodinger et al. found no significant associa-
tion between the Beijing genotype and either young age or
drug resistance (1). However, we have some caveats regard-
ing the comparison of these two studies. First, we restricted
our analysis to newly diagnosed patients to avoid confound-
ing by possible differences in relapse rates between
